Company Overview
| Stock Name | PW Medtech |
|---|---|
| Stock Code | 01358 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於中國醫療器械行業中快速增長及高利潤率分部的醫療器械公司,主要在骨科植入物及高端輸液器分部從事開發、生產及銷售。 |
| Listing Date | 2013-11-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區望京阜通東大街6號方恒國際中心C座505–506室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | pwmedtech.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 3.18 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.0001 / shares |
| Offer Period | 2013-10-31 to 2013-10-31 |
| Global Offering Shares | 400,000,000 shares |
| HK Public Offer Shares (Initial) | 40,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 360,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,600,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,272,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.52B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +519% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,784,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣100.2百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2010 | 2011 | 2012 | 2013-06 |
|---|---|---|---|---|
| Revenue | 60,816 | 175,267 | 331,541 | 218,750 |
| Cost of sales | -16,629 | -66,150 | -112,694 | -71,360 |
| Gross profit | 44,187 | 109,117 | 218,847 | 147,390 |
| Other income and gains, net | 30 | 866 | 1,570 | 251 |
| Selling and distribution expenses | -13,071 | -23,405 | -46,821 | -28,542 |
| Administrative expenses | -10,621 | -17,708 | -35,603 | -33,272 |
| Operating profit | 19,372 | 61,806 | 128,481 | 79,213 |
| Net finance costs | -2,104 | -4,478 | -8,760 | -4,869 |
| Profit before tax | 17,268 | 57,328 | 119,721 | 74,344 |
| Income tax expense | -2,936 | -7,982 | -19,538 | -14,104 |
| Profit for the year | 14,332 | 49,346 | 100,183 | 60,240 |
| Profit attributable to owners | 7,117 | 22,103 | 44,668 | 50,014 |
Balance Sheet
| Item | 2011 | 2012 | 2013-06 |
|---|---|---|---|
| Cash and cash equivalents | 1 | 106,055 | 4,488 |
| Total current assets | 1 | 106,079 | 9,394 |
| Total assets | 1 | 231,789 | 558,636 |
| Total liabilities | 9 | 23 | 7,643 |
| Total equity | -8 | 231,766 | 550,993 |
Cash Flow Statement
| Item | 2010 | 2011 | 2012 | 2013-06 |
|---|---|---|---|---|
| Net cash from operating activities | 11,735 | 15,713 | 24,906 | 31,494 |
| Net cash from investing activities | -24,002 | -246,714 | -117,581 | -28,545 |
| Net cash from financing activities | 63,336 | 230,001 | 244,030 | -73,010 |
| Net increase in cash | 51,069 | -1,000 | 151,355 | -70,061 |
| Purchase of PP&E | -19,987 | -38,039 | -26,463 | -1,634 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.51 |
|---|---|
| First Day Open | HK$ 3.18 |
| First Day Change | 10.38% |
| First Day Volume | 165294000.0 |
| First Day Turnover | 546880000.0 |
| Use of Proceeds | 所得款項凈額約50%或559.2百萬港元用于擴展我們的產能及投資于新產品的研發,包括
(i)約25%或279.6百萬港元用于購買生產設備
及完成我們位于北京及山東的新輸液器生產
廠房的建設;
(ii)約17%或190.1百萬港元用于拓展我們位于深圳及天津的骨科植入物廠房的產能;
(iii)約8%或89.5百萬港元投資于新產品的研發;
(2)所得款項凈額約30%或335.5百萬港元用于實
施我們的擴張計劃,包括作出收購及組件策略聯盟;
(3)所得款項凈額約10%或111.8百萬港元用于擴展我們的分銷網絡及銷售及營銷團隊,包括聘請專注專業的銷售員工;
(4)其余所得款項凈額最高約10%或111.8百萬港元的任何余額用作額外的營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (1)
Morgan Stanley Asia Limited CE AAD291
Joint Bookrunners (1)
Morgan Stanley Asia Limited CE AAD291
Joint Lead Managers (1)
Morgan Stanley Asia Limited CE AAD291
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 林君山 | — |
| Company Secretary | 傅偉霖 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | LIU女士及Cross Mark持股34.19%,WP X持股20.45%,陳國泰先生及Right Faith持股14.52%,李毅先生及Sparkle Wealthy持股5.84%。 |
|---|




